In patients with chronic myeloid leukemia and non-small cell lung cancer, ablation of F-box/WD repeat-containing protein 7 (FBXW7), a ubiquitin ligase that regulates dormancy by degrading cMyc and Notch (291), pushes CSCs out of dormancy and thus significantly enhances the benefit of imatinib and gefitinib, respectively (292, 293). This evidence concerns the gene FBXW7 and chronic myelogenous leukemia, BCR-ABL1 positive.